Oragenics to Present at Sidoti Micro-Cap Virtual Investor Conference

Oragenics Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company focused on neurological therapeutics, announced it will present and host one-on-one meetings with investors at Sidoti's Micro-Cap Virtual Investor Conference taking place May 20-21, 2026. The company's presentation is scheduled to begin at 3:15 p.m. ET on May 21, 2026, with additional virtual one-on-one investor meetings planned throughout the conference.

The announcement provides an opportunity for investors to learn more about Oragenics' lead candidate, ONP-002, a potential first-in-class treatment for concussion and mild traumatic brain injury delivered via the company's proprietary intranasal delivery technology. Oragenics is working on commencing clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow. The intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders.

Oragenics is a clinical-stage biotechnology company developing brain-targeted therapeutics. The company is committed to developing innovative therapies that address significant unmet medical needs in neurological care. For more information, visit oragenics.com.

The latest news and updates relating to OGEN are available in the company's newsroom at https://ibn.fm/OGEN. The full press release can be viewed at https://ibn.fm/MLd0Y.